Longevity Biotech is currently developing a portfolio of preclinical assets based on the Hybridtide scaffold. Hybridtides are peptides which consist of a blend of alpha and beta amino acids. It has been established that Hybridtides confer critical digestive stability, however we are excited to present the next step towards true oral peptide delivery. In addition, Hybridtides have demonstrated the ability to delivery biased GPCR signaling - which enables 'fine tuning' of eventual product profiles. We look forward to providing a peak into the state of the art in peptide stability and product profile development to the audience.